The global Peptide and Oligonucleotide CDMO (Contract Development and Manufacturing Organization) Market is undergoing transformative growth, driven by the rising prevalence of complex biologics, an expanding pipeline of nucleic acid therapeutics, and the biopharmaceutical industry's growing reliance on outsourced services for specialized manufacturing needs.
Global Peptide and Oligonucleotide CDMO Market size and share is currently valued at USD 2,078.37 million in 2024 and is anticipated to generate an estimated revenue of USD 4,646.57 million by 2032, according to the latest study by Polaris Market Research. Besides, the report notes that the market exhibits a robust 10.6% Compound Annual Growth Rate (CAGR) over the forecasted timeframe, 2024 - 2032
Market Overview
Peptides and oligonucleotides have emerged as powerful tools in modern medicine, offering high specificity, reduced side effects, and the potential to address previously untreatable conditions. Peptide drugs are increasingly used to manage metabolic diseases, cardiovascular conditions, and cancer. Meanwhile, nucleic acid therapeutics—including antisense oligonucleotides (ASOs), small interfering RNA (siRNA), and mRNA therapies—are being explored for genetic disorders, rare diseases, and infectious diseases.
The development and production of these therapeutic molecules require highly specialized infrastructure, advanced analytical capabilities, and a deep understanding of regulatory environments. CDMOs are uniquely positioned to deliver these services efficiently, ensuring that drug developers can focus on core R&D and innovation.
Market Segmentation
The Peptide and Oligonucleotide CDMO Market is segmented based on service type, product type, and end user:
By Service Type
Development Services: Includes process development, analytical method development, and formulation.
Manufacturing Services: Includes custom peptide synthesis and oligonucleotide manufacturing at various scales (clinical and commercial).
Packaging and Fill-Finish Services: Specialized for injectable peptide and oligonucleotide drugs.
By Product Type
Peptides: Includes synthetic peptides for therapeutic and diagnostic applications.
Oligonucleotides: Encompasses antisense oligos, siRNAs, mRNA, aptamers, and other nucleic acid-based drugs.
By End User
Pharmaceutical and Biotech Companies
Academic and Research Institutions
Diagnostic Labs and CROs
Each segment reflects varying degrees of demand, technical needs, and regulatory stringency, prompting CDMOs to continuously upgrade capabilities and maintain a high standard of GMP compliance.
Browse Full Insights:
https://www.polarismarketresearch.com/industry-analysis/peptide-and-oligonucleotide-cdmo-market
Regional Analysis
North America
North America commands the largest market share, driven by advanced healthcare infrastructure, high R&D spending, and early adoption of novel biologics. The U.S. leads with a strong base of biotech firms actively pursuing nucleic acid therapeutics and RNA-based innovations. CDMOs in the region have heavily invested in capacity expansion for oligonucleotide manufacturing, with a particular focus on high-purity, GMP-grade production.
Additionally, the presence of major regulatory agencies and a mature clinical trials ecosystem enables fast-track approvals and robust demand for CDMO services.
Europe
Europe is a significant contributor to market growth, with Germany, Switzerland, and the UK as key players. The region benefits from a well-established pharmaceutical manufacturing base and supportive regulatory policies. European CDMOs are known for quality and precision, with strong footprints in custom peptide synthesis for both therapeutic and cosmetic applications.
Rising investment in rare disease treatments and orphan drugs in Europe is increasing the need for flexible, small-batch manufacturing services—an area where peptide and oligonucleotide CDMOs thrive.
Asia-Pacific
Asia-Pacific is the fastest-growing regional market, fueled by increasing healthcare investments, government support for biopharma innovation, and cost-effective manufacturing. China and India are rapidly building their capacities in GMP-compliant peptide and oligonucleotide services to attract global clients.
Japan and South Korea are also advancing their roles as innovation hubs, focusing on mRNA therapeutics and personalized medicine. The expansion of clinical research and drug development pipelines in Asia is expected to create sustained demand for CDMO partnerships.
Latin America
Latin America is in the early stages of adopting CDMO outsourcing, but Brazil and Mexico are emerging markets showing promise. The region’s growing interest in biologics, including therapeutic peptides and RNA drugs, presents opportunities for localized manufacturing and development services.
Middle East and Africa
Though still developing, MEA’s market is gradually opening up with health infrastructure modernization, particularly in Gulf Cooperation Council (GCC) countries. Increased awareness of advanced therapies and initiatives to establish pharmaceutical hubs are anticipated to support CDMO market entry in the coming years.
Key Companies
The competitive landscape of the Peptide and Oligonucleotide CDMO Market features several global players known for innovation, regulatory excellence, and end-to-end service offerings. Leading companies in the market include:
Bachem Holding AG
A dominant player in custom peptide synthesis, Bachem offers an extensive range of services from process development to commercial manufacturing. The company has significantly expanded its peptide API capacity and is investing in oligonucleotide capabilities.
PolyPeptide Group
Specializing in GMP-grade peptides, PolyPeptide provides manufacturing services to major pharma and biotech clients worldwide. Its strong R&D and global footprint make it a preferred partner for complex peptide projects.
AGC Biologics
With recent acquisitions in oligonucleotide CDMOs, AGC Biologics has expanded its services in nucleic acid therapeutics, including plasmid DNA and mRNA manufacturing. It offers integrated biologics development and manufacturing solutions.
Thermo Fisher Scientific
Through Patheon, Thermo Fisher provides comprehensive CDMO services including oligonucleotide manufacturing for clinical and commercial use. The company has invested heavily in capacity expansion and next-generation synthesis platforms.
WuXi AppTec
A key player in Asia, WuXi AppTec offers end-to-end drug development and GMP-compliant manufacturing services for peptides and oligonucleotides. Its global facilities and seamless integration of R&D, manufacturing, and regulatory support are attractive to clients seeking speed and scalability.
Ajinomoto Bio-Pharma Services
This company offers both small- and large-scale custom peptide synthesis and is expanding into oligonucleotide production. Their strength lies in innovative technology platforms and consistent regulatory compliance.
CordenPharma
CordenPharma focuses on complex API manufacturing, including peptides and oligonucleotides. The company’s network of GMP facilities across Europe and the U.S. supports a wide range of therapeutic modalities.
These companies are competing based on scale, speed to market, regulatory support, and technological innovation. Many are expanding through strategic acquisitions, partnerships, and investment in next-generation platforms such as AI-driven process optimization and continuous manufacturing.
Conclusion
The Peptide and Oligonucleotide CDMO Market is poised for sustained expansion, driven by the increasing complexity of drug pipelines, a shift toward personalized and rare disease treatments, and the rising demand for GMP-compliant, specialized manufacturing services. As nucleic acid therapeutics gain traction across therapeutic areas, the role of CDMOs will continue to evolve from transactional service providers to strategic partners in drug development.
With strong market fundamentals, geographic expansion, and a clear need for expertise in custom peptide synthesis and oligonucleotide manufacturing, the industry is set to redefine the future of biopharmaceutical production. Key companies that can adapt, innovate, and scale rapidly are well-positioned to lead in this dynamic, high-growth space.
More Trending Latest Reports By Polaris Market Research:
South America Carbon Dioxide Market
Gynecomastia Procedures Market
